莫沙必利联合舒肝解郁胶囊治疗功能性消化不良的效果及对脑肠肽的影响

Curative effect of mosapride and Shugan Jieyu capsule in the treatment of functional dyspepsia and Influence on brain-gut peptide

目的探讨莫沙必利联合舒肝解郁胶囊治疗功能性消化不良（FD）的效果和机制。方法将110例FD患者按照随机数字表分为两组，每组55例，对照组应用莫沙必利片口服，5 mg/次，3次/d，餐前30 min服用；治疗组在对照组基础上联合舒肝解郁胶囊口服，2粒/次，2次/d，早晚温服，两组均连续治疗4周，比较两组治疗前后症状评分和治疗总有效率，并比较两组治疗前后血浆瘦素（Leptin）、胃促生长素（Ghrelin）和胃动素（MTL）水平，疗程结束后随访6个月，比较两组6个月的复发率。结果治疗后治疗组症状积分低于对照组[（4.97±1.85）分与（7.35±2.28）分，t＝6.011，P〈0.01]，治疗总有效率高于对照组[94.5%（52/55）与81.8%（45/55），χ2＝4.274，P＝0.039]，治疗组治疗后血浆Leptin低于对照组[（13.10±2.07） μg/L与（14.66±2.11） μg/L，t＝3.914，P＝0.001]，Ghrelin[（3.52±0.70） ng/L与（2.95±0.67） ng/L，t＝4.363，P〈0.01]、MTL[（281.47±61.09） ng/L与（242.31±65.28） ng/L，t＝3.248，P＝0.002]高于对照组，6个月复发率低于对照组[7.5%（5/53）与24.4%（11/45），χ2＝4.124，P＝0.041），差异均有统计学意义。结论莫沙必利联合舒肝解郁胶囊可有效改善FD症状，减少复发率，疗效确切，其机制可能与改善FD患者脑肠肽水平紊乱有关。

ObjectiveTo investigate the curative effect and mechanism of mosapride and Shugan Jieyu capsule in the treatment of functional dyspepsia（FD）.MethodsOne hundred and ten cases patients with FD were divided into two groups according to the digital random table method, with 55 cases in each group.The control group took mosapride tablets orally（5 mg/times, 3 times/d, 30 min before meals）, the treatment group took with Shugan Jieyu capsule orally（2 pellets/times, 2 times/d, orally with warm water on morning and evening） on the basis of treatment of the control group.Two groups were treated continuously for 4 weeks.The symptoms score and total effective before and after treatment were compared, and plasma Leptin（Leptin）, Ghrelin and gastric dynamic element（MTL） levels of the two groups before and after treatment were compared.The two groups were followed up for 6 months after treatment, the recurrence rate of the two groups was compared.ResultsThe symptoms integral of the treatment group after treatment was lower than that of the control group（（4.97±1.85） points vs.（7.35±2.28） points, t=6.011, P〈0.01）, the total effective rate was higher than that of the control group（94.5%（52/55） vs.81.8%（45/55）, χ2=4.274, P=0.039）, the improvement of plasma Leptin （（13.10±2.07） μg/L vs.（14.66±2.11） μg/L, t=3.914, P=0.001）, Ghrelin （（3.52±0.70） ng/L vs.（2.95±0.67）ng/L, t=4.363, P〈0.01）, MTL（（281.47±61.09） ng/L vs.（242.31±65.28） ng/L, t=3.248, P=0.002） levels were better than those of the control group, the recurrence rate of 6 months was lower than that of the control group（7.5%（5/53） vs.24.4%（11/45）, χ2=4.124, P=0.041）, the difference was statistically significant.ConclusionMosapride tablets combined with Shugan Jieyu capsule can benefit the liver symptom, and also can reduce the recurrence rate, it has curative effect on FD, its mechanism may be related to the improvement of BGP levels disorder in patients with FD.